Abbott Laboratories Company Profile (NYSE:ABT)

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories declared a quarterly dividend on Friday, June 9th. Stockholders of record on Friday, July 14th will be paid a dividend of $0.265 per share on Tuesday, August 15th. This represents a $1.06 dividend on an annualized basis and a dividend yield of 2.10%. The ex-dividend date of this dividend is Wednesday, July 12th. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) announced its quarterly earnings data on Thursday, July, 20th. The company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.60 by $0.02. The firm had revenue of $6.64 billion for the quarter, compared to analysts' expectations of $6.63 billion. Abbott Laboratories had a net margin of 4.96% and a return on equity of 15.53%. The business's quarterly revenue was up 24.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.55 EPS. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, October, 17th 2017. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories issued an update on its third quarter earnings guidance on Thursday, July, 20th. The company provided earnings per share guidance of $0.64-0.66 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.66. Abbott Laboratories also updated its FY17 guidance to $2.43-2.53 EPS.

14 brokers have issued 12 month target prices for Abbott Laboratories' stock. Their predictions range from $42.00 to $58.00. On average, they expect Abbott Laboratories' stock price to reach $52.77 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

Here are some recent quotes from research analysts about Abbott Laboratories stock:

• 1. According to Zacks Investment Research, "For the majority of last one month, Abbott is trading above the broader Medical Products industry. We are optimistic about the company’s strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Recently, Abbott received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging. The company also launched science-based nutrition drinks for better recovery from surgeries. On the flip side, Abbott’s sluggish pediatric business in China continues to hamper growth. Management is also concerned about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters." (6/21/2017)
• 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Some companies that are related to Abbott Laboratories include Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX), Patheon NV (PTHN), Taro Pharmaceutical Industries (TARO), Catalent (CTLT) and Akorn (AKRX).

Abbott Laboratories' management team includes the folowing people:

• Miles D. White, Chairman of the Board, Chief Executive Officer
• Brian B. Yoor, Chief Financial Officer, Senior Vice President - Finance
• Michael T. Rousseau, President - Cardiovascular and Neuromodulation
• Hubert L. Allen, Executive Vice President, General Counsel, Secretary
• Stephen R. Fussell, Executive Vice President - Human Resources
• Brian J. Blaser, Executive Vice President - Diagnostics Products
• John M. Capek Ph.D., Executive Vice President - Ventures
• Robert B. Ford, Executive Vice President - Medical Devices
• Heather L. Mason, Executive Vice President - Nutritional Products
• Roger Bird, Senior Vice President - U.S. Nutrition

Abbott Laboratories' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Diamond Hill Capital Management Inc. (0.69%), Vontobel Asset Management Inc. (0.22%), US Bancorp DE (0.19%), Rockefeller Financial Services Inc. (0.15%), Jarislowsky Fraser Ltd (0.14%) and NN Investment Partners Holdings N.V. (0.12%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including DnB Asset Management AS, APG Asset Management N.V., Bank of Montreal Can, Diamond Hill Capital Management Inc., Vontobel Asset Management Inc., Locust Wood Capital Advisers LLC, ING Groep NV and Russell Investments Group Ltd.. Company insiders that have sold Abbott Laboratories stock in the last year include Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including Hexavest Inc., Fisher Asset Management LLC, Mn Services Vermogensbeheer B.V., National Pension Service, Pennsylvania Trust Co, Aperio Group LLC, Sit Investment Associates Inc. and Jarislowsky Fraser Ltd. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Abbott Laboratories stock can currently be purchased for approximately $50.40.